.

BioPharmaceutical Business Intelligence

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Novartis
Argus Health
Mallinckrodt
Moodys
Express Scripts
US Army
Colorcon
Fuji
Fish and Richardson

Generated: December 17, 2017

DrugPatentWatch Database Preview

Taro Company Profile

« Back to Dashboard

What is the competitive landscape for TARO, and what generic alternatives to TARO drugs are available?

TARO has two hundred and eight approved drugs.

There are ten US patents protecting TARO drugs. There are three tentative approvals on TARO drugs.

There are sixty-two patent family members on TARO drugs in seventeen countries and seventy supplementary protection certificates in eleven countries.

Summary for Taro

International Patents:62
US Patents:10
Tradenames:109
Ingredients:92
NDAs:208
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
TaroCHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGYcetirizine hydrochlorideSYRUP;ORAL090182-002Apr 22, 2008OTCNoNo► Subscribe► Subscribe► Subscribe
TaroHYDROCORTISONE BUTYRATEhydrocortisone butyrateOINTMENT;TOPICAL076842-001Dec 27, 2004ABRXNoNo► Subscribe► Subscribe► Subscribe
Taro PharmGRANISETRON HYDROCHLORIDEgranisetron hydrochlorideTABLET;ORAL090817-001May 28, 2010ABRXNoNo► Subscribe► Subscribe► Subscribe
TaroETODOLACetodolacTABLET, EXTENDED RELEASE;ORAL076174-001Mar 13, 2003ABRXNoNo► Subscribe► Subscribe► Subscribe
TaroTAZAROTENEtazaroteneCREAM;TOPICAL208258-001Apr 3, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
TaroTOPICORTdesoximetasoneCREAM;TOPICAL017856-001Approved Prior to Jan 1, 1982DISCNYesNo► Subscribe► Subscribe► Subscribe
TaroCARVEDILOLcarvedilolTABLET;ORAL077780-003Sep 5, 2007ABRXNoNo► Subscribe► Subscribe► Subscribe
TaroHYDROCORTISONEhydrocortisoneLOTION;TOPICAL040247-001Jul 23, 1999ATRXNoNo► Subscribe► Subscribe► Subscribe
TaroFLO-PREDprednisolone acetateSUSPENSION;ORAL022067-002Jan 17, 2008DISCNNoNo► Subscribe► SubscribeY► Subscribe
TaroDIFLORASONE DIACETATEdiflorasone diacetateOINTMENT;TOPICAL075331-001May 14, 1999ABRXNoYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Taro

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Taro PharmsPLIAGLISlidocaine; tetracaineCREAM;TOPICAL021717-001Jun 29, 2006► Subscribe► Subscribe
TaroFLO-PREDprednisolone acetateSUSPENSION;ORAL022067-002Jan 17, 2008► Subscribe► Subscribe
TaroFLO-PREDprednisolone acetateSUSPENSION;ORAL022067-001Jan 17, 2008► Subscribe► Subscribe
TaroFLO-PREDprednisolone acetateSUSPENSION;ORAL022067-002Jan 17, 2008► Subscribe► Subscribe
TaroFLO-PREDprednisolone acetateSUSPENSION;ORAL022067-001Jan 17, 2008► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for TARO drugs

Drugname Dosage Strength Tradename Submissiondate
desoximetasoneTopical Spray0.25%TOPICORT12/18/2013
malathionTopical Lotion0.5%OVIDE3/16/2011

Premature patent expirations for TARO

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
► Subscribe ► Subscribe

Non-Orange Book Patents for Taro

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,957,238Process for preparing malathion for pharmaceutical use► Subscribe
5,886,038 Composition and method for treatment of psoriasis► Subscribe
8,206,727Oral suspension of prednisolone acetate► Subscribe
8,461,139Oral suspension of prednisolone acetate► Subscribe
8,536,155Process for preparing malathion for pharmaceutical use► Subscribe
8,039,657Process for preparing malathion for pharmaceutical use► Subscribe
6,355,258 Method for formulating spill resistant pharmaceutical compositions in semi-solid form► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Taro Drugs

Country Document Number Estimated Expiration
Austria345757► Subscribe
Japan5474347► Subscribe
European Patent Office2630951► Subscribe
Japan2012246315► Subscribe
European Patent Office1244401► Subscribe
Denmark1244401► Subscribe
Japan2003510259► Subscribe
Israel140000► Subscribe
Japan2009079053► Subscribe
BrazilPI0612686► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Taro Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0055France► SubscribePRODUCT NAME: SULFATE DE SODIUM ANHYDRE, SULFATE DE MAGNESIUM HEPTAHYDRATE, SULFATE DE POTASSIUM; NAT. REGISTRATION NO/DATE: NL41696 20130426; FIRST REGISTRATION: 434323 20130220
00085Netherlands► SubscribePRODUCT NAME: LEVOCETIRIZINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER LEVOCETIRINE DIHYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 26770 20011009; FIRST REGISTRATION: DE 49903.00.00 AND 49904.00.00 20010103
13/044Ireland► SubscribePRODUCT NAME: CLINDAMYCIN AND TRETINOIN; REGISTRATION NO/DATE: PA1332/043/001 20130322
60031Netherlands► SubscribePRODUCT NAME: DOXORUBICINESULFAAT VERKREGEN UIT DOXORUBICINEHYDROCHLORIDE EN AMMONIUMSULFAAT; REGISTRATION NO/DATE: EU/1/96/011/001 - EU/1/96/011/002 19960621
C0021Belgium► SubscribePRODUCT NAME: LANSOPRAZOLE + CLARITHROMYCINE + METRONIDAZOLE; REGISTRATION NO/DATE IN FRANCE: K 27 17033R DU 19960209; REGISTRATION NO/DATE AT EEC: K 27 17033R DU 19960209
C/GB11/054United Kingdom► SubscribePRODUCT NAME: BROMFENAC 2-AMINO-3-(4-BROMOBENZOYL)PHENYLACETIC ACID OR A PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF OR A HYDRATE THEREOF; REGISTERED: UK EU/1/11/692/001 20110523
269Luxembourg► SubscribePRODUCT NAME: AZELASTINE,OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUICI,ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE
14/032Ireland► SubscribePRODUCT NAME: DOLUTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, INCLUDING DOLUTEGRAVIR SODIUM; REGISTRATION NO/DATE: EU/1/13/892/001-002 20140121
2015 00014Denmark► SubscribePRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REG. NO/DATE: EU/1/14/983 20150119
14/058Ireland► SubscribePRODUCT NAME: SIMEPREVIR, OR A SALT THEREOF, INCLUDING SIMEPREVIR SODIUM; REGISTRATION NO/DATE: EU/1/14/924/001-002 20140516
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Fuji
US Army
Mallinckrodt
Deloitte
Colorcon
Covington
Accenture
McKesson
Moodys
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot